Pfiz­er's tur­moil; FTC's new tar­get; Aviv Regev Q&A; As­traZeneca's vac­cine gam­bit; Best of #ASH23; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Are you head­ed to San Fran­cis­co next month for JP Mor­gan? Whether at­tend­ing in per­son or vir­tu­al­ly, you’re in­vit­ed to join End­points’ pan­els and fire­sides. Learn more on how you can cus­tomize your ex­pe­ri­ence in John Car­roll’s col­umn here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER